anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Abnormal accumulation of misfolded and hyperphosphorylated tau protein in brain is the defining feature of several neurodegenerative diseases called tauopathies, including Alzheimer's disease (AD). In AD, this pathological change is reflected by highly specific cerebrospinal fluid (CSF) tau biomarkers, including both phosphorylated and non-phosphorylated variants. Interestingly, despite tau pathology being at the core of all tauopathies, CSF tau biomarkers remain unchanged in certain tauopathies, e.g., progressive supranuclear palsy (PSP), Pick's disease (PiD), and corticobasal neurodegeneration (CBD). To better understand commonalities and differences between tauopathies, we report a multiplex assay combining immunoprecipitation and high-resolution mass spectrometry capable of detecting and quantifying peptides from different tau protein isoforms as well as non-phosphorylated and phosphorylated peptides, including those carrying multiple phosphorylations. We investigated the tau proteoforms in soluble and insoluble fractions of brain tissue from subjects with autopsy-confirmed tauopathies, including sporadic AD (n = 10), PSP (n = 11), PiD (n = 10), and CBD (n = 10), and controls (n = 10). Our results demonstrate that non-phosphorylated tau profiles differ across tauopathies, generally showing high abundance of microtubule-binding region (MTBR)-containing peptides in insoluble protein fractions compared with controls; the AD group showed 12-72 times higher levels of MTBR-containing aggregates. Quantification of tau isoforms showed the 3R being more abundant in PiD and the 4R isoform being more abundant in CBD and PSP in the insoluble fraction. Twenty-three different phosphorylated peptides were quantified. Most phosphorylated peptides were measurable in all investigated tauopathies. All phosphorylated peptides were significantly increased in AD insoluble fraction. However, doubly and triply phosphorylated peptides were significantly increased in AD even in the soluble fraction. Results were replicated using a validation cohort comprising AD (n = 10), CBD (n = 10), and controls (n = 10). Our study demonstrates that abnormal levels of phosphorylation and aggregation do indeed occur in non-AD tauopathies, however, both appear pronouncedly increased in AD, becoming a distinctive characteristic of AD pathology.
Although recent propagation of carbapenemase-producing Enterobacterales (CPE) has become a problem worldwide, the picture of CPE infection in Japan has not fully been elucidated. In this study, we examined clinical and microbiological characteristics of invasive CPE infection occurring at 8 hospitals in Minami Ibaraki Area between July 2001 to June 2017. Of 7294 Enterobacterales strains isolated from independent cases of bacteremia and/or meningitis, 10 (0.14%) were CPE (8 Enterobacter cloacae-complex, 1 Escherichia coli, and 1 Edwardsiella tarda), all of which had the blaIMP-1 gene and susceptible to gentamicin and trimethoprim/sulfamethoxazole. These strains were isolated from 7 adult and 2 infant bacteremia (1 infant patient developed CPE bacteremia twice) after 2007. The most common portal of entry was intravenous catheters. All of the adult patients were recovered, while the infant patients eventually died. Genomic analyses showed that the 8 E. cloacae-complex strains were classified into 5 groups, each of which was exclusively detected in specific facilities at intervals of up to 3 years, suggesting persistent colonization in the facilities. This study showed that invasive CPE infection in the area was rare, caused by IMP-1-type CPE having susceptibility to various antibiotics, and nonfatal among adult patients.
APIVIRINE, extracted from Dichrostachys glomerata, is an antiviral drug made up of: gallic tannins, catechic tannins, alkaloids, flavonoids, saponosides, anthocyanins, leucoanthocyanins, steroids and terpenes, which together exhibit anti-COVID-19 activity. It can be used to cure and prevent coronavirus disease in symptomatic and asymptomatic patients and all exposed persons. Toxicological tests on rats are conclusive: APIVIRINE is non-toxic. The starting dose in cases requiring respiratory assistance is 12 capsules each containing 350 mg (orally or through a tube) of APIVIRINE powder obtained by incorporating 500 mg of pure lyophilised extract. Said dose is given three times a day in accordance with the half-life of APIVIRINE (four hours). For less severe cases and asymptomatic cases, the dose is three capsules three times a day and, for prevention, the dosage is one to two capsules three times a day. The absorption of APIVIRINE leads the coronavirus disappearing.
A system for providing disability-tailored therapy to a user having a disability with a presentation of the disability-tailored therapy compliant with accessibility requirements such that the presentation is accessible to the user having the disability is provided. The system includes a memory, a processor coupled to the memory programed with executable instructions, and a user device. The executable instructions cause the processor to obtain a disability-tailored therapy session for the user having the disability based on the disability. The user device configured to receive an input form the user and present the disability-tailored therapy session. The input is user information comprising the disability. The presentation is configured to be accessible to the user having the disability.
Nivolumab 480 mg intravenous (IV) solution for injection every 4 weeks until documented disease progression, discontinuation, withdrawal of consent, or the study ends or up to 4 doses in subjects without disease progression, whichever occurs earlier. After completing 4 doses of Nivolumab therapy, administer of CMAB819 480 mg intravenous (IV) solution for injection every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
1,255,672. Glycyrrhetinic acid esters. BIOREX LABORATORIES Ltd. 11 May, 1970 [6 June, 1969; 30 Oct., 1969], Nos. 28780/69 and 53213/69. Heading C2C. Compounds of formula (wherein R is an unsaturated aliphatic radical optionally substituted by an optionally substituted phenyl radical, or is a phenyl radical substituted by an unsaturated aliphatic radical and optionally also by further substituent(s); and R<SP>1</SP> is H or acyl; with the proviso that when R<SP>1</SP> is H, then R is other than an alkenyl radical of more than 10 carbon atoms) are prepared by reacting a 3-0-acyl-glycyrrhetinic acid chloride with a compound of formula ROH in the presence of pyridine under anhydrous conditions and at elevated temperature, whereafter, if desired, the 3-0-acyl group is removed by hydrolysis. The above defined products are claimed per se with the further exclusion of compounds wherein R is oleyl while R1 is oleoyl or stearoyl. The inventive compounds are stated to possess anti-ulcerative activity, and may be made up with carriers into pharmaceutical compositions for oral and parenteral administration.
Aclarubicin (6 mg/m²) will be administered intravenously through a central venous access device over 1 hour for four consecutive days (Days 2-5) of each 28 day cycle to each participant \[Retinal Vasculopathy with Cerebral Leukodystrophy (RVCL) patients\]. There is no maximum number of cycles.
The subject will receive a traditional medial off-loader brace and a take-home, self-guided exercise program. The subject will be instructed how to wear the brace. The subject will be instructed to incrementally increase wear time of the brace in the first week to get accustomed to the brace to reach a minimum of 6 hours per day after the first week.
PURPOSE:A polysaccharide gel plate having improved strength, comprising an aqueous solution of a polyhydric alcohol, wherein the polysaccharide contains at least carrageenan and galactomannan. CONSTITUTION:A polysaccharide gel plate comprising an aqueous solution of a polyhydric alcohol (e.g., sorbitol, glucose, sucrose, ethylene glycol, etc.) (preferably aqueous solution having a ratio of water to polyhydric alcohol of 95:5- 40:60 is used), wherein the polysaccharide contains at least carrageenan and galactomannan (its ratio is preferably 20:80-99:1). The concentration of the polysaccharide to be dissoved in the polyhydric alcohol is preferably 0.1-50wt%. It is usable as a base for fomentation, etc. It may be blended with a medicinal component (e.g., skin irritant such as methyl salicylate, antiphlogistic analgesic such as indomethacin, etc., antibiotic, etc.), a water-soluble high polymer inorganic salt, etc. according to the purpose of use.
In 5 AIDS patients with suspected Pneumocystis jiroveci pneumonia (PJP), the mean concentrations of pentamidine determined 18 to 24 hours after inhalation therapy were 23.2 ng/mL (range 5.1 to 43.0 ng/mL) in bronchoalveolar lavage fluid and 705 ng/mL (range 140 to 1336 ng/mL) in sediment after administration of a 300 mg single dose via the Respirgard ® II nebulizer. In 3 AIDS patients with suspected PJP, the mean concentrations of pentamidine determined 18 to 24 hours after a 4 mg/kg intravenous dose were 2.6 ng/mL (range 1.5 to 4.0 ng/mL) in bronchoalveolar lavage fluid and 9.3 ng/mL (range 6.9 to 12.8 ng/mL) in sediment. In the patients who received aerosolized pentamidine, the peak plasma levels of pentamidine were at or below the lower limit of detection of the assay (2.3 ng/mL). 

Following a single 2-hour intravenous infusion of 4 mg/kg of pentamidine isethionate to 6 AIDS patients, the mean plasma C max, T 1/2 and clearance were 612 ± 371 ng/mL, 6.4 ± 1.3 hr and 248 ± 91 L/hr respectively. In another study of aerosolized pentamidine in 13 AIDS patients with acute PJP who received 4 mg/kg/day administered via the Ultra Vent ® jet nebulizer, peak plasma levels of pentamidine averaged 18.8 ± 11.9 ng/mL after the first dose. During the next 14 days of repeated dosing, the highest observed C max averaged 20.5 ± 21.2 ng/mL. In a third study, following daily administration of 600 mg of inhaled pentamidine isethionate with the Respirgard ® II nebulizer for 21 days in 11 patients with acute PJP, mean plasma levels measured shortly after the 21st dose averaged 11.8 ± 10.0 ng/mL. Plasma concentrations after aerosol administration are substantially lower than those observed after a comparable intravenous dose. The extent of pentamidine accumulation and distribution following chronic inhalation therapy are not known. 

In rats, intravenous administration of a 5 mg/kg dose resulted in concentrations of pentamidine in the liver and kidney that were 87.5 and 62.3-fold higher, respectively, than levels in those organs following 5 mg/kg administered as an aerosol.

No pharmacokinetic data are available following aerosol administration of pentamidine in humans with impaired hepatic or renal function.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely, to otolaryngology, and can be used for the prevention of cicatricial deformities of the external nose in patients with open trauma of the nose body frame. 7–10 days after the initial surgical treatment of wounds and the elimination of post-traumatic deformities of the bone and cartilage skeleton of the external nose the treatment is started. During the first week, twice a day, skin is exposed to wounds with low-intensity laser radiation. Laser exposure is carried out by a labile contact method in the infrared range of the wavelength of 890 nm, in a pulsed mode with the pulse power of 7 W, and the frequency of 80 Hz. Sensor is moved over the specified area with stops up to 15 s every 1.5–2 cm. Total exposure time is 2 minutes. Five minutes after the laser exposure, the Contractubex gel is applied to the irradiated zone. During the second week, low-intensity laser radiation is not used, and the Contractubex gel is applied to the skin wound area twice a day. During the third week, the method used in the first week is repeated, and during the fourth week the method used in the second week is repeated.EFFECT: method allows to reduce the frequency of formation of cicatricial deformities in the area of the external nose due to the combined effect of the Contractubex gel and laser exposure.1 cl, 1 dwg, 2 tbl, 1 ex
With the increasingly severe situation of obesity and population aging, there is growing concern about sarcopenia obesity (SO). SO refers to the coexistence of obesity and sarcopenia, which imposes a heavier burden on individuals and society compared to obesity or sarcopenia alone. Therefore, comprehending the pathogenesis of SO and implementing effective clinical interventions are vital for its prevention and treatment. This review uses a comprehensive literature search and analysis of PubMed, Web of Science, and CNKI databases, with search terms including "Sarcopenic obesity", "exercise", "cytokines", "inflammation", "mitochondrial quality control", and "microRNA", covering relevant studies published up to July 2024. The results indicate that the pathogenesis of SO is complex, involving mechanisms like age-related changes in body composition, hormonal alterations, inflammation, mitochondrial dysfunction, and genetic and epigenetic factors. Regarding exercise interventions for SO, aerobic exercise can reduce fat mass, resistance exercise can increase skeletal muscle mass and strength, and combined exercise can achieve both, making it the optimal intervention for SO. The potential mechanisms by which exercise may prevent and treat SO include regulating cytokine secretion, inhibiting inflammatory pathways, improving mitochondrial quality, and mediating microRNA expression. This review emphasizes the effectiveness of exercise interventions in mitigating sarcopenic obesity through comprehensive analysis of its multifactorial pathogenesis and the mechanistic insights into exercise's therapeutic effects. Understanding these mechanisms informs targeted therapeutic strategies aimed at alleviating the societal and individual burdens associated with SO.
BACKGROUND: Direct peritoneal resuscitation (DPR) is associated with improved outcomes in trauma. Animal models suggest DPR has favorable effects on the liver. We sought to evaluate its safety and assess for improved outcomes in liver transplantation (LT).
METHODS: LT patients with renal dysfunction and/or obesity were enrolled in a phase-I clinical trial. DPR lasted 8-24 ​h depending on postoperative disposition. Primary outcome was percent of patients completing DPR. Secondary outcomes evaluated complications. Controls with either obesity (control-1) or both risk factors (obesity ​+ ​renal dysfunction, control-2) were analyzed.
RESULTS: Fifteen patients were enrolled (seven with both criteria and eight with obesity alone). DPR was completed in 87 ​% of patients, with one meeting stopping criteria. Controls included 45 (control-1) and 24 (control-2) patients. Return to operating room, graft loss, and late infections were lower with DPR.
CONCLUSION: DPR appears to be safe in closed abdomens following LT, warranting a follow-up phase-II trial to assess efficacy.
Up to 20 healthy monozygotic (MZ) individual twin volunteers, 2-20 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine or live, attenuated influenza vaccine quadrivalent (LAIV4) FluMist® Quadrivalent. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 7 and Day 28 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
A flexible thermal control composite comprising a natural or synthetic polymer and an endotherm dispersed, distributed and suspended within said natural or synthetic polymer i.e. “P”olymer “C”ontaining an “E”ndothermic “A”gent (PCEA). The PCEA can be formed into thin and thick films. It can be drawn, molded, extruded and spun into fibers or all dimensions. It can be formed and chopped into PCEA mulch. Irrespective its final form, the PCEA can be used in insulating, thermoprotecting, heat absorbing applications on the one hand, and heat maintenance applications of all types on the other.
The invention discloses a kind of pharmaceutical preparation and the preparation thereof that contain recombination human serum albumin-Filgrastim's fusion rotein.Does does is pharmaceutical preparation containing rHSA/G-CSF albumen of the present invention, lyophilized formulations, often prop up preparation and comprise following component: rHSA/G-CSF? albumen? 1-30mg; Pharmaceutically acceptable water soluble excipient? 10-80mg; Pharmaceutically acceptable protective agent? 5-30mg; PH value regulator? 5-50 μm of ol.Be applicable to the administrations such as subcutaneous or vein after pharmaceutical preparation containing rHSA/G-CSF albumen of the present invention is dissolved in water for injection, can neutrophilic granulocytopenia be treated by this pharmaceutical preparation of injecting applicable dosage.
Embodiments of the invention relate to a novel approach for determining the palatability, or preference, of foods, food stuffs, or veterinary biologics in animals. This approach provides a robust and reliable means of assessing palatability in animals using a cognitive palatability assessment protocol. The basic protocol utilizes a discrimination learning procedure, in which animals are presented with three simultaneous stimuli, such as objects, odors, sounds, digital pictures or projections, etc., and are allowed to respond to one, although any number of stimuli may be employed. The response is then recorded including metadata such as the rate of learning, response rate and response order for example. Depending on the animal's choice, the response will typically result in the animal receiving no reward, or either of two particular foods, food stuffs or veterinary biologics. The animal's response selection is indicative of a preference for one food, food stuff or veterinary biologic over the other and is indicative of the palatability of one food, food stuff or veterinary biologic in comparison to the other. This method requires the use of fewer animals than alternative approaches and may prove healthier for animals that do not self-limit their food consumption.
The invention relates to a preparation method of animal model simulating human pelvic inflammatory disease (PID). The method comprises the steps of selecting animal of family Muridae without reproductive tract diseases; and under sterile condition, inoculating strain of genus Enterobacter, genus Staphylococcus or genus Candida in animal vagina for 1-8 weeks and 1-7 times every week. The invention has the advantages of high model preparation success ratio and no dependence on immunity inhibitor. After success of model preparation, vaginal secretion obviously increases; bacteria can be observed by vaginal smear microscopic examination; metryperemia, abscess and ovarian cyst can be observed after dissection. Large amount of inflammatory cell infiltration can be observed in uterus and oviduct by organ tissue section microscopic examination. Blood examination indicates abnormal rise of neutrophil count. The method has the advantages of simple implementation, easily-accessible materials, easy grasping without special technical requirements for operator, accordance with clinical natural occurrence process of PID, and suitability for research of generation, development and mechanism of PID and screening of relevant drugs.
Patients receive 4 telehealth sessions over 1 hour each over 4 months. Patients also receive an intervention guidebook.
For those participants who additionally agree to participate in the muscle microdamage portion of the study, participants will be asked to return to the lab 24h and 48h post-trial. During these subsequent follow-up sessions, an additional blood sample will be drawn from the participants, the participants maximal voluntary contraction and muscle pain will be assessed, and they will be asked to fill out the muscle soreness scale.
Disclosed are a fused heterocyclic compound, a preparation method therefor, a pharmaceutical composition, and uses thereof. The fused heterocyclic compound is shown in formula I, formula II, or formula III. The preparation method of the fused heterocyclic compound and/or the pharmaceutically acceptable salt thereof in the present invention comprises three synthesizing routes. The present invention also provides a pharmaceutical composition of the fused heterocyclic compound, the pharmaceutical composition containing one or more of the fused heterocyclic compound shown in formula I, formula II, or formula III, the pharmaceutically acceptable salt thereof, hydrates, solvent compounds, polymorphs and prodrugs thereof, and a pharmaceutically acceptable carrier. The present invention also relates to an application of the fused heterocyclic compound and/or the pharmaceutical composition in preparing kinase inhibitors and in preparing drugs for preventing and treating diseases related to kinase. The fused heterocyclic compound of the present invention has selective inhibition function on PI3K δ , and can be used for preparing drugs for preventing and treating cell proliferation diseases such as cancers, infections, inflammations, or autoimmune diseases.
Participants received 0.5 mg fingolimod orally once a day for up to 24 months during the core phase. In the Extension phase participants continued to receive 0.5 mg fingolimod orally once a day.
Brain endothelial low-density lipoprotein receptor related protein-1 (LRP-1)  mediates vascular clearance of Alzheimer's amyloid-.beta. peptide (A.beta.) from the brain. Transport of A.beta. occurs across the blood-brain barrier (BBB) to the systemic circulation, but the brain endothelium is compromised in Alzheimer's disease. The invention is used to diagnose the disease in symptomatic and asymptomatic individuals, to identify those at risk for disease or already affected thereby, to determine the stage of disease or it s progression, to intervene earlier in or alter the disease's natural history,  to provide a target for therapeutic or prophylactic treatments, to screen drugs or compare medical regimens, to determine the effectiveness of a drug or medical regimen, or any combination thereof.
PURPOSE:The titled pharmaceutical containing a bismuth compound as an active ingredient. CONSTITUTION:A side effect reducing agent, obtained by containing a bismuth compound, e.g. bismuth subnitrate, bismuth subgallate, bismuth subsalicylate, etc., as an active ingredient and useful for anthracycline based antibiotic substances. The anthracycline antibiotic substances are glycosides of 7,8,9,10- tetrahydro-5,12-naphthacenequinone and mainly produced by actinomyces. Examples thereof include daunomycin, etc., having high antitumor action and useful as a carcinostatic agent though with powerful side effect on the bone marrow and heart. The above-mentioned side effec reducing agent is orally administered in 6-10g dose divided in 3-5 portions in the dosage form of tablet, granule, powder, capsule, suspension, etc., before using the above- mentioned antibiotic substances.
The present invention relates to a mask sheet and a mask pack using the same. More specifically, the mask sheet is eco-friendly and has electrical conductivity and antibacterial properties. According to the present invention, the mask pack includes the mask sheet which is woven with conductive fibers including a copper component and cotton fibers. The mask pack can be prepared without preservatives or with a minimum amount of preservatives therein by using the antibacterial properties of the mask sheet. The antibacterial properties of the mask sheet can be used to easily alleviate skin troubles caused by bacteria. The conductivity of the mask sheet can be used to make the mask sheet display anti-static properties while enhancing the absorbency of beneficial components by using electrical stimuli.